Long-term Cognitive and Functional Impact of Proton-therapy or Modern Fractionated Radiotherapy in Cavernous Sinus Meningioma: An Open-label Randomized 1:1 Phase III Study

Recruiting N/A Interventional Study
Cavernous Sinus Meningioma Proton-therapy Photon Radiotherapy Cognitive Impairment
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 70
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
160 (estimated)
Sponsor
Centre Francois Baclesse · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Cavernous sinus meningiomas are close to optic nerve, pituitary gland, cranial nerve, and hippocampi. The doses delivered to these structures are crucial and radiotherapy of cavernous sinus meningiomas exposes patients to late secondary effects (pituitary deficit, nerve palsy, cognitive impairment…). In 2012, Gondi reported that a dose given to 40% of the bilateral hippocampi greater than 7.3 Gy …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Cavernous sinus meningioma for which clinical target volume is larger than 3 centimeters * Anterior skull base meningioma, invading by contiguity the cavernous sinus can be included * Histologic proven Grade I meningioma * Meningioma for which biopsy is not safely achievable a…
Contacts

Jeanne RIVERAIN, MD

+33 2 31 45 50 50

j.riverain@baclesse.unicancer.fr

CONTACT

Jean-Michel GRELLARD

+33 2 31 45 50 50

jm.grellard@baclesse.unicancer.fr

CONTACT